Clinical trials: HIV/AIDS
HIV Infections
A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (MK0518-018 EXT2)
This study will investigate the safety and efficacy of raltegravir as a therapy for HIV-infected patients failing current therapy with 3-class antiviral resistance.
- Trial name
- NCT00293267
- Testing
- raltegravir potassium
- Volunteers
- 352 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis B Vaccine
Immunogenicity of Hepatitis B Vaccination in HIV-infected Adults
Uptake, adherence, and completion of vaccination among HIV-infected adults were low, and their immune function and immune response to hepatitis B vaccination were also suboptimal, indicating that the current practice of hepatitis…
- Trial name
- HIV (NCT03316807)
- Testing
- 60 µg dose hepatitis B vaccine, 20 µg dose hepatitis B vaccine
- Volunteers
- 182 people
- Sponsor
- Suping Wang
HIV Infections
Pilot Study on the Effect of Adding Raltegravir +/- a Second Drug on HIV Levels in the Gut
The "PLUS" study is a pilot study to measure the effect of therapy intensification (with raltegravir and optional second agent) on HIV levels in the gut and blood in patients on antiretroviral therapy (ART) with viral load < 50…
- Trial name
- PLUS (NCT00884793)
- Testing
- raltegravir, Study NNRTI, Study PI
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- University of California, San Francisco
HIV, Rabies
Immune Response After Booster Vaccination in HIV - Infected Patients Who Received Rabies Primary Vaccination
Booster rabies vaccination in HIV - infected patients who have ever received rabies primary vaccination could improve their immune response to this kind of vaccine.
- Trial name
- NCT01286493
- Testing
- rabies vaccines on day 0 and 3
- Where
- Thailand
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Queen Saovabha Memorial Institute
Adherence, Depression
Skills Based Counseling for Adherence and Depression in HIV+ Methadone Patients - 1
Patients with HIV, depression, and opioid-dependence are at high risk for poor health outcomes. This is a two-arm randomized controlled trial of cognitive-behavioral therapy for depression and HIV medication adherence in patients…
- Conditions
- Adherence, Depression, Heroin Dependence, Methadone
- Trial name
- NCT00218634
- Testing
- CBT-AD, ETAU
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- Massachusetts General Hospital
HIV-1 Infection
A Study to Assess the Efficacy of Raltegravir (Isentress®), Administered in Combination With Other Antiretroviral Drugs as Treatment for Adults and Older Adults Infected With the Human Immunodeficiency Virus 1 (HIV-1)(MK-0518-145) (Wirksamkeit Von Isentress® Unter Praxisbedingungen)
This is an observational, non-comparative, multicenter, open-label study. Participants will be treated with Raltegravir according to standard clinical practice, and monitored over a total period of 96 weeks.
- Trial name
- WIP (NCT01213316)
- Testing
- Raltegravir
- Volunteers
- 451 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV
Enfuvirtide/Current Protease Inhibitor Switch to PREZISTA (Darunavir)/Ritonavir + TMC125 in HIV Patients With Enfuvirtide Side Effects.
The purpose of this study is to examine the safety, tolerability, and effectiveness of darunavir/ritonavir combined with TMC125 when current protease inhibitor(s), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI(s)) and…
- Trial name
- NCT00460746
- Testing
- TMC125, Darunavir; Ritonavir
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Tibotec, Inc
Hiv, Substance Use Disorders
PrEP at a Syringe Services Program
The purpose of this study is to see if providing participants with pre-exposure prophylaxis (PrEP) medicine right away at the IDEA Exchange will help participants remain in HIV negative.
- Trial name
- NCT04782180
- Testing
- Descovy 200Mg 25Mg Tablet, PrEP
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- University of Miami
HIV Infection
MK0518 in the Treatment of HIV-Infected Patients Switched From a Protease Inhibitor Regimen (0518-033)(TERMINATED)
The purpose of this study is to investigate the efficacy, safety, and tolerability of an investigational treatment for patients with Human Immunodeficiency Virus (HIV).
- Trial name
- NCT00443729
- Testing
- Comparator: raltegravir, Comparator: lopinavir (+) ritonavir
- Volunteers
- 355 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV
A Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1
The purpose of this study was to evaluate the safety, tolerability, and pharmacokinetics (PK) of dolutegravir (DTG) in infants born to mothers living with HIV-1.
- Trial name
- NCT05406583
- Testing
- Dolutegravir 0.5 mg/kg liquid suspension (starts at 0-5 days of life), Dolutegravir 5 mg Dispersible Tablets (single doses), Dolutegravir 5 mg Dispersible Tablets (chronic dose)
- Where
- 15 sites in United States, South Africa and 1 more
- Volunteers
- 96 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Microbicide Delivery System Perceptibility and Acceptability
Developing Rectal USPE Measures for Suppositories (Project DRUM-S)
The purpose of this study is to (a) adapt existing user sensory perception and experience (USPE) items/instruments generated for rectal gel/cream formulations to include USPEs specific to suppository forms for rectal and vaginal…
- Trial name
- DRUM-S (NCT02744261)
- Testing
- Gel, Suppository 1, Suppository 2
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- The Miriam Hospital
Advanced Malignant Solid Neoplasm, HIV Infection
Cabozantinib S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus
This phase I trial studies the side effects and best dose of cabozantinib s-malate in treating patients with solid tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment and…
- Conditions
- Advanced Malignant Solid Neoplasm, HIV Infection, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm
- Trial name
- NCT01822522
- Testing
- Cabozantinib S-malate, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 20 sites in United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Infection, Human Immunodeficiency Virus, HIV Infections
A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)
This study is designed to demonstrate the non-inferior antiviral activity of DTG/ABC/3TC fixed dose combination (FDC) once daily (OD) compared to atazanavir plus ritonavir (ATV+RTV) and tenofovir disoproxil fumarate/emtricitabine…
- Trial name
- NCT01910402
- Testing
- Dolutegravir/abacavir/lamivudine FDC, Atazanavir, Ritonavir
- Where
- 90 sites in United States, Argentina and 11 more
- Volunteers
- 499 people
- Sponsor
- ViiV Healthcare
HIV/AIDS
PlusCare: Mobile Platform to Increase Linkage to Care in Adolescents Living With HIV/AIDS
While major advancements in medical technology over the past decade have significantly improved the life expectancy of persons infected with human immunodeficiency virus (HIV), HIV-positive youth today face new barriers to the…
- Trial name
- NCT03758066
- Testing
- PlusCare
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Dimagi Inc.
HIV-1 Infection
Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC
The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of switching abacavir/lamivudine (ABC/3TC) fixed-dose combination (FDC) tablets to emtricitabine/tenofovir alafenamide (F/TAF) FDC…
- Trial name
- NCT02469246
- Testing
- F/TAF, ABC/3TC, 3rd ARV agent
- Where
- 80 sites in United States, Belgium and 10 more
- Volunteers
- 567 people
- Sponsor
- Gilead Sciences
Human Immunodeficiency Virus (HIV)
Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)
The primary purpose of this study is to assess the rate of early discontinuation from randomized Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) for any reason other than confirmation of the negative HIV…
- Trial name
- PEPDar (NCT01516970)
- Testing
- Darunavir/Ritonavir (DRV/r), Lopinavir in fixed combination with Ritonavir, Zidovudine
- Where
- 17 sites in Germany
- Volunteers
- 312 people
- Sponsor
- Janssen-Cilag G.m.b.H
HIV Infections
Management of Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Antiretroviral (ARV) Combination Therapy Including Raltegravir (MK-0518-138)
To evaluate the management of HIV-1 participants treated with antiretroviral combination therapy including the integrase inhibitor raltegravir, all across the country of France.
- Trial name
- RACING (NCT01048671)
- Testing
- Raltegravir, ARV (non-raltegravir)
- Volunteers
- 482 people
- Sponsor
- Merck Sharp & Dohme LLC
Pre-Exposure Prophylaxis
Developing mHealth to Promote PrEP Use Among Thai Young Men Who Have Sex With Men
The goal of this study is to develop and pilot test technology-based interventions to promote Pre-exposure Prophylaxis (PrEP) uptake and adherence among Thai young men who have sex with men (YMSM).
- Trial name
- NCT05243030
- Testing
- Motivational Enhancement System for PrEP Uptake and Adherence (MES-PrEP), Motivational Interactive Text Messaging (MTM), Standard PrEP Counseling
- Where
- 3 sites in Thailand
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- University of Massachusetts, Worcester
Human Immunodeficiency Virus, Perinatal Depression
Adaptation of the Friendship Bench Intervention for HIV-infected Perinatal Women in Lilongwe
In many sub-Saharan African countries, the scale-up of lifelong antiretroviral treatment (ART) to all pregnant and breastfeeding women under Option B+ has the potential to radically improve maternal health and reduce…
- Trial name
- Periscope (NCT04143009)
- Testing
- Enhanced Friendship Bench, Enhanced Standard Care (Control), Adapted Friendship Bench
- Where
- 3 sites in Malawi
- Volunteers
- 92 people
- Sponsor
- University of North Carolina, Chapel Hill
HIV-1-infection
ART First-line Treatment Durability in Russia
This study is a non-interventional retrospective study. Data from patients who signed informed consent form will be collected through retrospective chart or medical records review.
- Trial name
- NCT04253119
- Testing
- Antiretroviral/Anti HIV
- Where
- 4 sites in Russia
- Volunteers
- 536 people
- Sponsor
- MSD Pharmaceuticals LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.